Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Lola-Jade PalmieriLaurent MineurDavid TougeronBenoît RousseauVictoire GrangerJean-Marc GornetDenis SmithAstrid LievreMarie-Pierre GalaisSolene DoatSimon PernotAnne-Laure Bignon-BretagneJean-Philippe MetgesNabil Baba-HamedPierre MichelStéphane ObledCarole VitelliusOlivier BoucheLéa Saban-RocheBruno BuecherGaëtan des GuetzChristophe LocherIsabelle TrouilloudGaël GoujonMarie DiorSylvain ManfrediEmilie SoularueJean-Marc PhelipJulie HenriquesDewi VerneryRomain CoriatPublished in: The oncologist (2019)
For RAS/RAF wild-type metastatic colorectal cancer, patients may receive 5-fluorouracil-based chemotherapy plus either bevacizumab or an anti-epidermal growth factor receptor (EGFR). In daily practice, the time to obtain the RAS status might be long enough to consider two options: to start the chemotherapy with bevacizumab, or to start without a targeted therapy and to add the anti-EGFR at reception of the RAS status. This study found no deleterious effect of the delayed introduction of an anti-EGFR on survival, compared with the introduction of an anti-vascular endothelial growth factor from cycle 1. It is possible to wait one or two cycles to introduce the anti-EGFR while waiting for RAS status.
Keyphrases
- epidermal growth factor receptor
- wild type
- tyrosine kinase
- small cell lung cancer
- advanced non small cell lung cancer
- vascular endothelial growth factor
- squamous cell carcinoma
- primary care
- healthcare
- physical activity
- clinical trial
- type diabetes
- locally advanced
- insulin resistance
- metabolic syndrome
- radiation therapy
- cross sectional
- rectal cancer
- glycemic control